Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification

Parkinson's disease (PD) is a progressive and debilitating chronic disease that affects more than six million people worldwide, with rising prevalence. The hallmarks of PD are motor deficits, the spreading of pathological α-synuclein clusters in the central nervous system, and neuroinflammatory...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2022-05, Vol.13, p.878771-878771
Main Authors: Grotemeyer, Alexander, McFleder, Rhonda Leah, Wu, Jingjing, Wischhusen, Jörg, Ip, Chi Wang
Format: Article
Language:English
Subjects:
animal models
Immunology
microglia
neurodegeneration
neuroinflammation
Parkinson’s disease
T cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson's disease (PD) is a progressive and debilitating chronic disease that affects more than six million people worldwide, with rising prevalence. The hallmarks of PD are motor deficits, the spreading of pathological α-synuclein clusters in the central nervous system, and neuroinflammatory processes. PD is treated symptomatically, as no causally-acting drug or procedure has been successfully established for clinical use. Various pathways contributing to dopaminergic neuron loss in PD have been investigated and described to interact with the innate and adaptive immune system. We discuss the possible contribution of interconnected pathways related to the immune response, focusing on the pathophysiology and neurodegeneration of PD. In addition, we provide an overview of clinical trials targeting neuroinflammation in PD.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.878771